Immunotherapy Response Monitoring in Lung Cancer

Roy S. Herbst, MD, PhD, reviews currently available treatment options in immunotherapy in non-small-cell lung cancer and approaches to monitoring treatment response.

EP. 1: Treatment Options in Non–Small Cell Lung Cancer

October 18th 2021

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

EP. 2: Monitoring Response to Therapy in NSCLC

October 18th 2021

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

EP. 3: Role of ctDNA in Monitoring Treatment Response in NSCLC

October 25th 2021

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

EP. 4: Clinical Decision-Making in NSCLC

October 25th 2021

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

EP. 5: Recap: Monitoring With ctDNA for Immunotherapy Response in Lung Cancer

January 1st 2022

Roy S. Herbst, MD, PhD, discussed implementing immunotherapy and seeing its effectiveness in patients with lung cancer.

EP. 6: OncView™ Podcast: Immunotherapy Response Monitoring in Lung Cancer

April 1st 2022

In an OncView program, Roy Herbst, MD, PhD, touched on clinical decision-making, monitoring response, and the potential treatment options available for treating non–small cell lung cancer.